Benjamin S C Wade1, Gerhard Hellemann2, Randall T Espinoza3, Roger P Woods, Shantanu H Joshi1, Ronny Redlich4, Anders Jørgensen5, Christopher C Abbott6, Ketil J Oedegaard7, Shawn M McClintock8, Leif Oltedal, Katherine L Narr. 1. From the Department of Neurology, University of California Los Angles (UCLA), Ahmanson-Lovelace Brain Mapping Center. 2. Department of Psychiatry and Biobehavioral Sciences, Semel Institute. 3. Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA. 4. Department of Psychiatry, University of Münster, Münster, Germany. 5. Psychiatric Center Copenhagen, Copenhagen, Denmark. 6. Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM. 7. Department of Clinical Medicine, University of Bergen, Bergen, Norway. 8. Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX.
Abstract
OBJECTIVE: Symptom heterogeneity in major depressive disorder obscures diagnostic and treatment-responsive biomarker identification. Whether symptom constellations are differentially changed by electroconvulsive therapy (ECT) remains unknown. We investigate the clustering of depressive symptoms over the ECT index and whether ECT differentially influences symptom clusters. METHODS: The 17-item Hamilton Depression Rating Scale (HDRS-17) was collected from 111 patients with current depressive episode before and after ECT from 4 independent participating sites of the Global ECT-MRI Research Collaboration. Exploratory factor analysis of HDRS-17 items pre- and post-ECT treatment identified depressive symptom dimensions before and after ECT. A 2-way analysis of covariance was used to determine whether baseline symptom clusters were differentially changed by ECT between treatment remitters (defined as patients with posttreatment HDRS-17 total score ≤8) and nonremitters while controlling for pulse width, titration method, concurrent antidepressant treatment, use of benzodiazepine, and demographic variables. RESULTS: A 3-factor solution grouped pretreatment HDRS-17 items into core mood/anhedonia, somatic, and insomnia dimensions. A 2-factor solution best described the symptoms at posttreatment despite poorer separation of items. Among remitters, core mood/anhedonia symptoms were significantly more reduced than somatic and insomnia dimensions. No differences in symptom dimension trajectories were observed among nonremitting patients. CONCLUSIONS: Electroconvulsive therapy targets the underlying source of depressive symptomatology and may confer differential degrees of improvement in certain core depressive symptoms. Our findings of differential trajectories of symptom clusters over the ECT index might help related predictive biomarker studies to refine their approaches by identifying predictors of change along each latent symptom dimension.
OBJECTIVE: Symptom heterogeneity in major depressive disorder obscures diagnostic and treatment-responsive biomarker identification. Whether symptom constellations are differentially changed by electroconvulsive therapy (ECT) remains unknown. We investigate the clustering of depressive symptoms over the ECT index and whether ECT differentially influences symptom clusters. METHODS: The 17-item Hamilton Depression Rating Scale (HDRS-17) was collected from 111 patients with current depressive episode before and after ECT from 4 independent participating sites of the Global ECT-MRI Research Collaboration. Exploratory factor analysis of HDRS-17 items pre- and post-ECT treatment identified depressive symptom dimensions before and after ECT. A 2-way analysis of covariance was used to determine whether baseline symptom clusters were differentially changed by ECT between treatment remitters (defined as patients with posttreatment HDRS-17 total score ≤8) and nonremitters while controlling for pulse width, titration method, concurrent antidepressant treatment, use of benzodiazepine, and demographic variables. RESULTS: A 3-factor solution grouped pretreatment HDRS-17 items into core mood/anhedonia, somatic, and insomnia dimensions. A 2-factor solution best described the symptoms at posttreatment despite poorer separation of items. Among remitters, core mood/anhedonia symptoms were significantly more reduced than somatic and insomnia dimensions. No differences in symptom dimension trajectories were observed among nonremitting patients. CONCLUSIONS: Electroconvulsive therapy targets the underlying source of depressive symptomatology and may confer differential degrees of improvement in certain core depressive symptoms. Our findings of differential trajectories of symptom clusters over the ECT index might help related predictive biomarker studies to refine their approaches by identifying predictors of change along each latent symptom dimension.
Authors: George I Papakostas; Timothy Petersen; John Denninger; Shamsah B Sonawalla; Yasmin Mahal; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava Journal: Psychiatry Res Date: 2003-05-01 Impact factor: 3.222
Authors: Shawn M McClintock; Mustafa M Husain; Ira H Bernstein; Stephen R Wisniewski; Madhukar H Trivedi; David Morris; Jonathan Alpert; Diane Warden; James F Luther; Susan G Kornstein; Melanie M Biggs; Maurizio Fava; A John Rush Journal: Int J Methods Psychiatr Res Date: 2011-11-04 Impact factor: 4.035
Authors: Benjamin S C Wade; Jing Sui; Stephanie Njau; Amber M Leaver; Megha Vasvada; Boris A Gutman; Paul M Thompson; Randal Espinoza; Roger P Woods; Christopher C Abbott; Katherine L Narr; Shantanu H Joshi Journal: Proc IEEE Int Symp Biomed Imaging Date: 2017-06-19
Authors: H A Sackeim; J Prudic; D P Devanand; M S Nobler; S H Lisanby; S Peyser; L Fitzsimons; B J Moody; J Clark Journal: Arch Gen Psychiatry Date: 2000-05
Authors: Amber M Leaver; Randall Espinoza; Tara Pirnia; Shantanu H Joshi; Roger P Woods; Katherine L Narr Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2016-01
Authors: Andrew T Drysdale; Logan Grosenick; Jonathan Downar; Katharine Dunlop; Farrokh Mansouri; Yue Meng; Robert N Fetcho; Benjamin Zebley; Desmond J Oathes; Amit Etkin; Alan F Schatzberg; Keith Sudheimer; Jennifer Keller; Helen S Mayberg; Faith M Gunning; George S Alexopoulos; Michael D Fox; Alvaro Pascual-Leone; Henning U Voss; B J Casey; Marc J Dubin; Conor Liston Journal: Nat Med Date: 2016-12-05 Impact factor: 53.440
Authors: Benjamin S C Wade; Shantanu H Joshi; Stephanie Njau; Amber M Leaver; Megha Vasavada; Roger P Woods; Boris A Gutman; Paul M Thompson; Randall Espinoza; Katherine L Narr Journal: Neuropsychopharmacology Date: 2016-04-12 Impact factor: 7.853
Authors: Benjamin S C Wade; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Shantanu H Joshi; Ronny Redlich; Udo Dannlowski; Anders Jorgensen; Christopher C Abbott; Leif Oltedal; Katherine L Narr Journal: Hum Brain Mapp Date: 2021-08-13 Impact factor: 5.038
Authors: Benjamin S C Wade; Joana Loureiro; Ashish Sahib; Antoni Kubicki; Shantanu H Joshi; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Eliza Congdon; Katherine L Narr Journal: Psychol Med Date: 2022-05-17 Impact factor: 10.592